{"entity":{"id":"bruce-levine","kind":"person","name":"Bruce L. Levine","aka":[],"tldr":"Built the manufacturing that turned CAR-T from a lab idea into a product given to thousands of patients.","summary":"Bruce L. Levine is the Barbara and Edward Netter Professor in Cancer Gene Therapy and Founding Director of the Clinical Cell and Vaccine Production Facility at the Abramson Cancer Center, University of Pennsylvania. He is known for building the manufacturing that turned CAR-T from a laboratory idea into a product given to thousands of patients, including co-developing the CTL019 manufacturing process. His selected paper reviews global manufacturing of CAR T cell therapy. He is a past president of the International Society for Cell & Gene Therapy and continues to work on cell therapy manufacturing and in vivo CAR-T.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levine%20BL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","in-vivo-car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Barbara and Edward Netter Professor in Cancer Gene Therapy; Founding Director, Clinical Cell and Vaccine Production Facility","institutionId":"penn-abramson","specialisms":["Cell therapy manufacturing","CAR-T","Translational immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levine%20BL%5BAuthor%5D"}],"papers":[{"title":"Global manufacturing of CAR T cell therapy","journal":"Molecular Therapy Methods & Clinical Development","year":2017,"url":"https://doi.org/10.1016/j.omtm.2016.12.006","doi":"10.1016/j.omtm.2016.12.006"},{"title":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1709866","doi":"10.1056/NEJMoa1709866"},{"title":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1407222","doi":"10.1056/NEJMoa1407222"}],"orcid":"0000-0001-6971-8465"},"route":"/people/bruce-levine/","neighbours":{"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"institution":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/"}],"person":[{"id":"emily-whitehead","kind":"person","name":"Emily Whitehead","route":"/people/emily-whitehead/"}],"paper":[{"id":"paper-eliana-tisagenlecleucel-nejm-2018","kind":"paper","name":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL","route":"/key-papers/paper-eliana-tisagenlecleucel-nejm-2018/"},{"id":"paper-maude-ctl019-all-nejm-2014","kind":"paper","name":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","route":"/key-papers/paper-maude-ctl019-all-nejm-2014/"}]}}